Neural Therapeutics Inc.
NURL
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.93% | 183.19% | 336.22% | 11.89% | -21.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.65% | 123.69% | 137.47% | -35.21% | -41.77% |
| Operating Income | 45.65% | -123.69% | -137.47% | 35.21% | 41.77% |
| Income Before Tax | 36.91% | 182.06% | -664.05% | 37.64% | 36.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.91% | 182.06% | -664.05% | 37.64% | 36.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.91% | 182.06% | -664.05% | 37.64% | 36.57% |
| EBIT | 45.65% | -123.69% | -137.47% | 35.21% | 41.77% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 72.73% | 160.87% | -521.43% | 50.00% | 50.00% |
| Normalized Basic EPS | 71.43% | -100.00% | -77.78% | 46.67% | 46.15% |
| EPS Diluted | 72.73% | 160.87% | -521.43% | 50.00% | 50.00% |
| Normalized Diluted EPS | 71.43% | -100.00% | -77.78% | 46.67% | 46.15% |
| Average Basic Shares Outstanding | 139.31% | 34.72% | 20.53% | 23.05% | 21.65% |
| Average Diluted Shares Outstanding | 139.31% | 34.72% | 20.53% | 23.05% | 21.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |